Ipsilateral irradiation for well lateralized carcinomas of the oral cavity and oropharynx: results on tumor control and xerostomia by Cerezo, Laura et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Radiation Oncology
Open Access Research
Ipsilateral irradiation for well lateralized carcinomas of the oral 
cavity and oropharynx: results on tumor control and xerostomia
Laura Cerezo*1, Margarita Martín1, Mario López1, Alicia Marín1 and 
Alberto Gómez2
Address: 1Department of Radiation Oncology, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain and 
2Department of Medical Physics, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain
Email: Laura Cerezo* - lcerezo.hlpr@salud.madrid.org; Margarita Martín - margamm@yahoo.es; Mario López - mlopezrgez@yahoo.es; 
Alicia Marín - amarin.hlpr@salud.madrid.org; Alberto Gómez - ag_barrado@yahoo.es
* Corresponding author    
Abstract
Background: In head and neck cancer, bilateral neck irradiation is the standard approach for many
tumor locations and stages. Increasing knowledge on the pattern of nodal invasion leads to more
precise targeting and normal tissue sparing. The aim of the present study was to evaluate the
morbidity and tumor control for patients with well lateralized squamous cell carcinomas of the oral
cavity and oropharynx treated with ipsilateral radiotherapy.
Methods:  Twenty consecutive patients with lateralized carcinomas of the oral cavity and
oropharynx were treated with a prospective management approach using ipsilateral irradiation
between 2000 and 2007. This included 8 radical oropharyngeal and 12 postoperative oral cavity
carcinomas, with Stage T1-T2, N0-N2b disease. The actuarial freedom from contralateral nodal
recurrence was determined. Late xerostomia was evaluated using the European Organization for
Research and Treatment of Cancer QLQ-H&N35 questionnaire and the National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE), version 3.
Results: At a median follow-up of 58 months, five-year overall survival and loco-regional control
rates were 82.5% and 100%, respectively. No local or contralateral nodal recurrences were
observed. Mean dose to the contralateral parotid gland was 4.72 Gy and to the contralateral
submandibular gland was 15.30 Gy. Mean score for dry mouth was 28.1 on the 0-100 QLQ-H&N35
scale. According to CTCAE v3 scale, 87.5% of patients had grade 0-1 and 12.5% grade 2 subjective
xerostomia. The unstimulated salivary flow was > 0.2 ml/min in 81.2% of patients and 0.1-0.2 ml/
min in 19%. None of the patients showed grade 3 xerostomia.
Conclusion:  In selected patients with early and moderate stages, well lateralized oral and
oropharyngeal carcinomas, ipsilateral irradiation treatment of the primary site and ipsilateral neck
spares salivary gland function without compromising loco-regional control.
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Background
Radiation therapy is an effective treatment for head and
neck cancer patients, showing a high success rate in the
early stages of disease. However, permanent xerostomia is
a common complication, frequently compromising nutri-
tion and speech, and accelerating dental decay [1]. Xeros-
tomia is caused from bilateral irradiation of the major
serous-producing glands, mainly the parotids, and the
minor salivary glands which significantly contribute to
mucinous secretion [2]. There is not yet an effective treat-
ment for this late complication once it has occurred,
thereby, reducing the patient's quality of life.
Head and neck squamous cell carcinomas (HNSCC) are
characterized by a relatively orderly spread to regional cer-
vical lymph nodes. Generally, elective neck irradiation is
not recommended when the risk of subclinical disease is
less than 15-20% [3]. There is growing evidence in the lit-
erature that patients with early oropharyngeal and oral
cavity cancer have a low incidence of contralateral node
involvement, hence, radiation therapy can be limited to
the ipsilateral neck, without compromising loco-regional
control [4-7]. However, bilateral neck irradiation contin-
ues to be the standard approach for most patients, espe-
cially those with ipsilateral clinical node-positive
presentation. One argument for the continued inclusion
of the contralateral neck is that morbidity is low using
Intensity Modulated Radiation Therapy (IMRT), because
parotid sparing can be easily achieved with this technique
[8,9]. However, IMRT is not yet universally available, and,
certainly, morbidity will be still lower if only one side of
the neck is treated.
In our department three-dimensional conformal radia-
tion therapy (3D-CRT) was started a decade ago, and
guidelines for unilateral elective nodal irradiation in
patients with HNSCC were implemented soon after [10].
The purpose of the current study was to report on morbid-
ity and tumor control for patients with well lateralized
squamous cell carcinomas of the oral cavity and orophar-
ynx treated with the ipsilateral technique. These results
will contribute to some previous experiences supporting
this conservative approach.
Methods
Patients
Twenty patients with early stage HNSCC, where the risk of
contralateral neck node involvement was estimated to be
less than 15-20%, [3,11-13] were treated with unilateral
irradiation between 2000 and 2007. The guidelines for
inclusion in the unilateral protocol were as follows: histo-
logically confirmed squamous cell carcinoma; location of
the lesion in the tonsillar region with less than 1 cm of
medial extension to the soft palate or to the base of the
tongue, retromolar trigone, lateral alveolar ridge, cheek
mucosa or lateral border of tongue; tumor stage T1-T2 and
nodal stage N0, N1, N2a or N2b, according to TNM clas-
sification of the UICC-AJCC [14]. Patients with N2 disease
up to two ipsilateral nodes, less than 2 cm in diameter,
were included in the study, but not those with three or
more nodes.
Patients were assessed by clinical examination, by both
the head and neck surgeon and the radiation oncologist,
endoscopy and CT scan of the head and neck region. A
chest X-ray or chest CT and blood test were performed to
rule out distant metastases. Patients were treated with pri-
mary or postoperative RT with curative intent. Postopera-
tive RT was given to patients with oral carcinomas
presenting close (less than 5 mm) or positive margins, or
for cases of extracapsular nodal extension in the patholog-
ical specimen. Two patients received postoperative chem-
otherapy, concomitantly with RT. Table 1 shows the
demographic, tumor and treatment characteristics of
patients. No patient in the present series was treated with
contralateral neck dissection. The study was approved by
the ethical committee of the hospital, and informed con-
sent was obtained from all patients.
Table 1: Demographic, tumor and treatment characteristics of 
the 20 patients
Characteristics Number (%)
Age, mean (range) 60 (31- 94) 20 (100%)
Sex 12 (60%)
M1 2  ( 6 0 % )
F8  ( 4 0 % )
Tumor site
Oral cavity 12 (60%)
Lateral border of tongue 6 (30%)
Retromolar trigone 2 (10%)
Lateral alveolar ridge 3 (15%)
Cheek mucosa 1 (5%)
Oropharynx 8 (40%)
Tonsil 5 (25%)
Tonsillar pillar 3 (15%)
T stage
T1 6 (30%)
T2 12 (60%)
T4* 2 (10%)
N stage
N0 11 (55%)
N1 4 (20%)
N2a-b 5 (25%)
Radiation treatment
Primary 8 (40%)
Postoperative 12 (60%)
Concomitant chemotherapy
Yes 2 (10%)
No 18 (90%)
* Two patients with alveolar ridge and retromolar trigone carcinomas 
with bone erosion.Radiation Oncology 2009, 4:33 http://www.ro-journal.com/content/4/1/33
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Radiotherapy technique
All patients were treated using 3D-CRT. The high dose vol-
ume included the gross tumor or the surgical tumor bed
with 5 mm set-up margin (PTV1). The elective target
included the elective ipsilateral nodal levels with 5 mm
set-up margin (PTV2). The guidelines used for the selec-
tion of ipsilateral nodal target volume are described in
Table 2. The total dose prescribed to the primary tumor
was 66-70 Gy for patients with gross disease and 54-64 Gy
for patients treated in the adjuvant setting. For elective
radiotherapy, 50 Gy was administered to the ipsilateral
regions at risk of subclinical disease (PTV2), both for rad-
ical and postoperative radiotherapy. All patients were
treated with continuous, conventional fractionation of 2
Gy, one fraction per day, five fractions per week.
The contralateral parotid and submandibular glands, as
well as the spinal cord, were outlined on the planning CT-
scan. The goal of treatment planning was maximal exclu-
sion of the contralateral parotid gland, while providing
adequate coverage of the target. The most common
arrangement used was a two- or three-field ipsilateral
technique (Figures 1 and 2). In some cases, where the PTV
was more medial, a contralateral field was used to increase
the dose homogeneity of the deep part of the target,
always sparing the parotid gland. The use of wedges in
some fields was common.
Follow-up
Patients were followed every 3-4 months during the first
two years, every 6 months until 5 years, and once yearly
until 10 years. Radiation oncologists and head and neck
surgeons performed a clinical examination. A head and
neck CT or MRI, examination under general anesthesia
and/or biopsy were performed if recurrence was sus-
pected.
Assessment of xerostomia and quality of life
All patients were contacted by phone and given an
appointment to assess their morbidity. They completed
the EORTC QLQ-H&N35 questionnaire [15] where items
are rated on a four-point scale and normalized to a
number between 0 and 100. Higher scores represent
worse symptoms. The questionnaire was translated for use
among Spanish patients [16]. Items 41 (Have you had a
dry mouth?) and 42 (Have you had sticky saliva?), directly
related to xerostomia, and item 37 (Have you had prob-
lems swallowing solid food?), related to dysphagia, and
indirectly related to xerostomia, were analyzed in the
present study.
Xerostomia was also graded according to the Common
Terminology Criteria for Adverse Events (CTCAE) radia-
tion morbidity grading scale, version 3.0 [17]. The CTC
evaluation of xerostomia included subjective patient rat-
ing, and objective measurement of the unstimulated sali-
vary output, collecting the saliva spit by the patient into a
plastic cup for five minutes at least two hours after break-
fast. The saliva was weighed on a precision balance and
then saliva flow was calculated assuming 1 g saliva was
equal to 1 ml saliva [18].
No salivary stimulating or protective agents such as pilo-
carpine or amifostine were allowed during the study.
Statistical analysis
Survival data and loco-regional control rates were ana-
lyzed from the initiation of radiation treatment using the
Kaplan-Meier method. A descriptive analysis was used for
the toxicity data. SPSS 16.0 for Windows was used for the
statistical analysis.
Results
Patients
Twenty patients consecutively treated with unilateral radi-
otherapy in 2000-2007 were included in this study. No
patients treated in this period with the unilateral tech-
nique were excluded from the analysis. Eight patients
(40%) underwent primary RT while 12 patients (60%)
underwent postoperative RT. All patients had T1-T2 squa-
mous cell carcinomas, except two patients with alveolar
ridge and retromolar trigone carcinomas, respectively,
that were staged pT4 because minimal bone invasion was
found in the surgical specimen. Eleven patients were node
negative and 9 patients had N1 or N2 disease.
Dose distribution
According to dose-volume histograms, the mean dose
administered to the contralateral parotid gland was 4.72
Gy (range, 1-10 Gy) and to the contralateral submandib-
Table 2: Ipsilateral nodal target volumes
Tumor site Stage Nodal levels included
Tonsillar fossa T1-2 N0
T1-2 N1-2
II, III
II-IV, RP*
Lateral border of tongue T1-2 N0
T1-2 N1-2
Ib, II, III
Ia, Ib, II, III, IV
Retromolar trigone, lateral alveolar ridge, cheek mucosa T1-2 N0
T1-2 N1-2
Ib, II, III
Ia, Ib, II, III,IV
RP: retropharyngeal lymph nodesRadiation Oncology 2009, 4:33 http://www.ro-journal.com/content/4/1/33
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ular gland 15.30 Gy (range, 1-37 Gy). At least 95% of the
target volumes received 97%-105% of the prescribed
dose. Mean dose to the PTV1 was 67.5 Gy (range, 64-71
Gy) for primary RT and 58 Gy (range, 54-64 Gy) for post-
operative RT. The mean dose to the PTV2 (elective ipsilat-
eral lymph nodes) was 51 Gy (range, 49-52 Gy). The
average mean dose to the spinal cord was 8 Gy (range, 1-
18 Gy).
Disease control
With a median follow-up of 58 months, the 5-year overall
survival and loco-regional control rates were 82.5% and
100%, respectively. No loco-regional recurrences were
found in these patients. Six patients developed a second
primary cancer at a median follow-up of 3 years (range, 2-
6 years), four of whom died. Pulmonary non-small cell
carcinoma was the most frequent type (3 cases), followed
by hepatocellular carcinoma (2 cases) and anal carcinoma
(1 case).
Xerostomia
Sixteen patients (80%) filled out the EORTC QLQ H&N35
questionnaire at the concerted visit, at least 1 year after the
completion of RT. Mean score for dry mouth was 28.1 on
a scale of 0-100, and 26.5 for sticky saliva; mean score for
dysphagia was 4.6 on the same scale (Table 3).
When evaluating patients according to the CTCAE v3.0
classification at the same visit, 5 patients (31.2%) had
grade 1 xerostomia and 9 patients (56.2%) had no xeros-
tomia symptoms. Two patients (12.5%) showed grade 2
xerostomia. No grade 3 subjective xerostomia was found
among these patients (Table 4).
Oropharyngeal cancer Figure 1
Oropharyngeal cancer. A representative example of a 
CT-based dose plan for a patient with a T2N0M0 tonsillar 
carcinoma treated with a pair of ipsilateral wedged fields. 
Green line: PTV1, treated to 70 Gy; red line: PTV2 including 
ipsilateral II, III and retropharyngeal lymph node levels, 
treated with 50 Gy. Contralateral parotid and part of the 
oral cavity are preserved from significant radiation.
 P  70 Gy 
50 Gy 
Oral cavity cancer Figure 2
Oral cavity cancer. Patient with a pT2N0M0 carcinoma of 
the left lateral border of tongue treated with postoperative 
radiation therapy for close margin and perivascular- 
perineural invasion. Ipsilateral technique using three ports: 
anterior, left posterior oblique and left lateral. Green line: 
PTV1, treated to 60 Gy; blue line: PTV2 including ipsilateral 
Ib, II and III node levels, treated to 50 Gy; cyan line: contral-
ateral parotid, yellow line: contralateral submandibular; mean 
dose to the right parotid 8 Gy, mean dose to the submandib-
ular gland 20 Gy.
Table 3: Xerostomia scores from the EORTC QLQ H&N35 
scale
Scale item Mean Median Range
Dry mouth (item 41) 28.1 25 (0-50)
Sticky saliva (item 42) 26.5 25 (0-50)
Dysphagia (item 37) 4.6 0 (0-25)
Results from 16 patients who were alive at last follow-up. The QLQ 
scores were normalized to a number between 0 and 100. Higher 
numbers, worse symptoms.Radiation Oncology 2009, 4:33 http://www.ro-journal.com/content/4/1/33
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Unstimulated saliva flow was > 0.2 ml/min (grade 0-1
xerostomia) in 13 patients (81.2%), and 0.1-0.2 ml/min
(grade 2 xerostomia) in 3 patients (18.7%). No grade 3
objective xerostomia (< 0.1 ml/min) was found in the
measurements (Table 4, Figure 3).
Discussion
Morbidity resulting from irradiation in the head and neck
area can be reduced significantly by a comprehensive def-
inition of the CTV, i.e. excluding the contralateral neck in
a selected group of patients. A double objective was
intended with the ipsilateral technique applied in the
present study: to preserve salivary gland function while
maintaining loco-regional control. The first was achieved
given no grade 3 xerostomia and only 12.5% grade 2 sub-
jective xerostomia were found in our series. The absence
of loco-regional recurrences, more specifically, the
absence of isolated contralateral neck recurrences, dem-
onstrated the second.
The major benefit of ipsilateral radiation treatment is to
provide the opportunity for salivary protection by exclu-
sion of the contralateral major salivary glands and part of
the oral cavity mucosa. The mean dose of 4.72 Gy admin-
istered to the opposite parotid in our study is well below
the dose of 26 Gy recommended by most authors to pre-
serve salivary function. Accordingly, the subjective and
objective scores for xerostomia reported in our series were
low. Eisbruch et al [1] observed a recovery from xerosto-
mia in unilaterally irradiated patients which was accom-
panied with a compensatory overproduction of saliva in
the contralateral parotid and submandibular gland at 12-
24 months. Furthermore, Jellema [19] found that the
mean dose given to the contralateral parotid gland was the
most important prognostic factor for patient-rated xeros-
tomia.
In general, the CTCAE v3.0 proved to be a practical and
adequate tool to measure late xerostomia, since it has two
components, a subjective one, based on patient com-
plaints, and an objective part, based on unstimulated sal-
ivary flow measurements. However, the salivary flow
values do not always correspond to the level of symptoms
reported by patients. For example, one patient with sali-
vary flow 0.1-0.2 ml/min, corresponding to a grade 2
objective finding, rated her symptoms as only a grade 1
subjective xerostomia and gave a score of 25 for dry
mouth on the H&N35 scale. This finding was further ana-
lyzed by Jensen et al [20] who found little correlation
between patient-assessed symptom scores according to
EORTC questionnaires C30 and H&N35 and objective
findings, including saliva flow measurements. Eisbruch et
al [1] also described a low correlation between symptoms
and salivary measurements. They concluded that both
subjective side effects questionnaires and measurement of
the saliva should be included in the xerostomia evalua-
tion. As the main objective of minimizing side effects is to
improve patient quality of life, subjective symptoms are
more relevant, at least in clinical practice.
As expected, this group of patients fared well in terms of
loco-regional control and survival, since their tumor bur-
den was low. Generally, elective neck irradiation is not
recommended where the risk of subclinical disease is less
than 20%, because of the morbidity of radiotherapy. The
results of the present study demonstrate that the failure
rate in the opposite neck is rare in selected cases with well
lateralized tumors of the tonsillar region and oral cavity.
In fact, no contralateral neck recurrences were found in
any of the twenty treated patients. Jackson [4] and O'Sul-
livan [5] found similar results, with 2.2% and 3.5% con-
tralateral failure rates, respectively, in two large
oropharyngeal cancer series that also included some N+
patients. Other authors reporting on oral cavity and
oropharyngeal cancer found a low incidence of contralat-
eral nodal failure (0-3%), although studying fewer
patients [6,7,21].
There are frequent scenarios where unilateral irradiation
can be applied when treating HNSCC. In the oral cavity,
surgery is the most frequent treatment for T1-T2 tumors,
however, if margins are positive or close, or if invaded
Table 4: Frequency and grade of xerostomia according to CTCAE v3.0 scale
Endpoint Grade 0
N (%)
Grade 1
N (%)
Grade 2
N (%)
Grade 3
N (%)
Subjective
Xerostomia No complains of xerostomia Dry or thick saliva Significant dietary alteration Inability to adequately aliment orally
9 (56.2%) 5 (31.2%) 2 (12.5%) 0 (0%)
Objective
Salivary flow > 0.2 ml/min > 0.2 ml/min 0.1-0.2 ml/min < 0.1 ml/min
* 13 (81.2%) 3 (18.7%) 0 (0%)
Results from 16 patients who were alive at the evaluation date;
* Unstimulated salivary flow for Grade 1 is equal to Grade 0Radiation Oncology 2009, 4:33 http://www.ro-journal.com/content/4/1/33
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lymph nodes are found, postoperative radiotherapy is
commonly indicated to reduce the risk of loco-regional
recurrence. Although some authors [8,9] recommend
bilateral irradiation when nodal invasion is found in the
ipsilateral neck, perhaps a watching policy with close fol-
low-up can be adopted, since the risk for contralateral
metastases is still low. The recent report by Rusthoven et
al on 20 patients with node-positive tonsil cancer treated
with ipsilateral technique and without contralateral neck
recurrence illustrates this approach well [22].
Some radiation oncologists are still reluctant to spare the
contralateral neck in head and neck cancer patients. This
prejudice can be originated in the former standard tech-
niques, because a pair of parallel lateral fields assured
good coverage of the target in the bi-dimensional radio-
therapy era. Thus, bilateral elective neck irradiation
remains the prevailing option for many tumor sites and
stages. However, the better knowledge of the pattern of
nodal invasion and the advent of three-dimensional plan-
ning has brought along higher precision in the delinea-
tion of targets, including the nodal targets in the neck.
This may allow a progressively conservative tendency in
the head and neck radiation treatment. Furthermore, it is
feasible that the indications for unilateral techniques will
broaden in the near future, once experience is gained for
the various tumor sites.
Two patients treated in the last year of the study received
postoperative chemoradiation, based on high risk patho-
logical factors: extracapsular nodal invasion in one patient
and positive resection margin in the other. The objective
of adding concurrent chemotherapy in these patients was
to increase the loco-regional control probability. As the
recommendations for postoperative chemoradiation are
relatively recent [23], we found only one publication on
patients with high associated risk factors treated with ipsi-
lateral irradiation plus chemotherapy [22]. This should be
further investigated in future studies.
A key question when considering unilateral irradiation,
apart from local tumor extension and nodal status, is how
a possible contralateral recurrence will be managed.
Advances in radiographic and PET imaging have made
staging and subsequent follow-up more accurate, allow-
ing for better detection of occult contralateral lymph node
metastases. A neck dissection can usually be performed
with little morbidity if an isolated contralateral nodal
recurrence occurs. However, patients should be involved
in the decision to use this approach when the risk is mod-
erate (e.g. those with established regional nodal disease).
A close follow-up program is mandatory in these patients
in order to diagnose and rescue a possible recurrence as
soon as possible.
The observed incidence of late grade 2 xerostomia in the
present series compared favorably with other reports of
patients treated with parotid-sparing bilateral IMRT
[7,24]. This was likely related to the combined sparing of
the contralateral parotid and part of the contralateral sub-
mandibular gland. Certainly, the salivary function can be
further preserved using ipsilateral IMRT because the major
salivary glands and some part of the oral cavity can be
avoided by the radiation ports. In this regard, Par-
vathaneni et al [25] have reported on the superiority of
IMRT over the wedge pair technique for unilateral treat-
ment of tonsil carcinoma in terms of parotid sparing and
conformality of the dose, although the mean dose to the
contralateral submandibular gland was not significantly
different. As the 3D-CRT ipsilateral technique is simpler to
perform and gives acceptable good results, it seams rea-
sonable to reserve IMRT for more advanced stages for
whom bilateral neck irradiation is deemed necessary.
Additional methods reported to improve salivary produc-
tion and reduce xerostomia include protection of the sali-
vary glands by daily amifostine during RT [26] or
stimulation with pilocarpine [27]. These methods could
only be complementary to planning efforts aimed at
reducing the dose given to the major salivary glands and
to the oral cavity. For example, Burlage et al [27] reported
Salivary flow rates Figure 3
Salivary flow rates. Unstimulated salivary flow rates in ml/
min in 16 available subjects at least 1 year after treatment. 
Above the horizontal bar are 13 patients with normal salivary 
flow ≥ 0.2 ml/min. Only three patients are located below 
the horizontal bar, with salivary flow < 0.2 ml/min (grade 2 
toxicity).
URadiation Oncology 2009, 4:33 http://www.ro-journal.com/content/4/1/33
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some benefit of prophylactic pilocarpine when the
parotid gland was irradiated with a mean dose above
40 Gy.
Other functions like swallowing can be better kept with
the ipsilateral technique since less healthy tissues, like the
pharyngeal constrictor muscles, are irradiated. In our
series only 3 patients had some problem swallowing solid
food, while the rest had no complaints. Swallowing func-
tion is closely related with salivation, and the reduced rate
of dysphagia in these patients could have been influenced
by the normal salivary function in most of them.
One could also hypothesize that morbidity of the radia-
tion treatment may influence overall survival in head and
neck patients, since xerostomia can cause malnutrition,
dental infections and other debilitating conditions. Some
authors comparing ipsilateral and bilateral irradiation in
larger series have found better overall survival within the
ipsilateral treatment group [6].
Conclusion
In summary, using an ipsilateral technique in selected
patients with well lateralized squamous cell carcinoma of
the oral cavity or oropharynx reports clinical benefits,
sparing the salivary gland function without compromis-
ing loco-regional control. Although the outcomes with
ipsilateral RT in the present series were promising, these
findings require validation in a larger patient cohort, espe-
cially for oral cavity cancer.
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